Leerink analyst Joseph Schwartz downgraded AN2 Therapeutics to Market Perform from Outperform with a $7 price target after the company decided to voluntarily pause Phase 3 enrollment in its Phase 2/3 clinical trial evaluating epetraborole in treatment-refractory mycobacterium avium complex lung disease, pending further data review.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ANTX:
